blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1833968

EP1833968 - CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  21.02.2014
Database last updated on 15.06.2024
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU		published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
Viventia Biotechnologies Inc.
7895 Tranmere Drive, Suite 204
Mississauga, ON L5S 1V9 / CA
[2012/36]
Former [2007/38]For all designated states
Viventia Biotech Inc.
5060 Spectrum Way, Suite 405
Mississauga ON L4W 5N5 / CA
Inventor(s)01 / GLOVER, Nicholas, R.
2389 Deer Run Avenue
Oakville, Ontario L6J 6K7 / CA
02 / MACDONALD, Glen
475 Raglan Rd.
Winnipeg, Manitoba R3G 3E4 / CA
03 / ENTWISTLE, Joycelyn
380 Lindenwood Drive East
Winnipeg, Manitoba R3P 2H1 / CA
04 / CIZEAU, Jeannick
602-170 Hargrave Street
Winnipeg, Manitoba R3C 3H4 / CA
05 / CHAHAL, Francina, C.
1344 Lee Boulevard
Winnipeg, Manitoba R3T 6E2 / CA
 [2007/47]
Former [2007/38]01 / GLOVER, Nicholas, R.
2389 Deer Run Avenue
Oakville, Ontario L6J 6K7 / CA
02 / MACDONALD, Glen
475 Raglan Rd.
Winnipeg, Manitoba R3G 3E4 / CA
03 / ENTWISTLE, Joycelyn
380 Lindenwood Drive East
Winnipeg, Manitoba R3P 2H1 / CA
04 / CIZEAU, Jeannick
602-170 Hargrave Street
Winnipeg, Manitoba R3C 3H4 / CA
05 / CHAHAL, Francina, C.
185 Victor Lewis Drive
Winnipeg, Manitoba R3P 2A2 / CA
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2013/37]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham
NG1 5GG / GB
Former [2013/16]Wright, Andrew John
Potter Clarkson LLP The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Former [2011/01]Wright, Andrew John
Potter Clarkson LLP Park View House 58 The Ropewalk
Nottingham NG1 5DD / GB
Former [2007/38]Miles, John Stephen
Eric Potter Clarkson LLP Park View House 58 The Ropewalk
Nottingham NG1 5DD / GB
Application number, filing date05823959.121.12.2005
[2007/38]
WO2005CA01953
Priority number, dateUS20040637448P21.12.2004         Original published format: US 637448 P
[2007/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2006066408
Date:29.06.2006
Language:EN
[2006/26]
Type: A1 Application with search report 
No.:EP1833968
Date:19.09.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 29.06.2006 takes the place of the publication of the European patent application.
[2007/38]
Type: B1 Patent specification 
No.:EP1833968
Date:17.04.2013
Language:EN
[2013/16]
Search report(s)International search report - published on:CA29.06.2006
(Supplementary) European search report - dispatched on:EP17.08.2009
ClassificationIPC:C12N15/13, G01N33/574, G01N33/53, A61K31/7088, A61K39/395, A61K39/00
[2007/38]
CPC:
C07K16/30 (EP,US); A61K39/001102 (EP,US); A61P35/00 (EP);
A61P35/02 (EP); A61P35/04 (EP); A61P37/04 (EP);
C07K16/303 (EP,US); C07K16/3046 (EP,US); C07K16/3053 (EP,US);
C07K16/3069 (EP,US); G01N33/57488 (EP,US); C07K2317/21 (EP,US);
C07K2317/41 (EP,US); C07K2317/51 (EP,US); C07K2317/55 (EP,US);
C07K2317/565 (EP,US); C07K2317/92 (EP,US); G01N2500/10 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/38]
TitleGerman:KREBSSPEZIFISCHER ANTIKÖRPER UND ZELLOBERFLÄCHENPROTEINE[2007/38]
English:CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS[2007/38]
French:ANTICORPS SPECIFIQUE DU CANCER ET PROTEINES DE SURFACE CELLULAIRE[2007/38]
Entry into regional phase20.07.2007National basic fee paid 
20.07.2007Search fee paid 
20.07.2007Designation fee(s) paid 
20.07.2007Examination fee paid 
Examination procedure20.07.2007Examination requested  [2007/38]
11.11.2009Amendment by applicant (claims and/or description)
27.04.2011Despatch of a communication from the examining division (Time limit: M04)
26.08.2011Reply to a communication from the examining division
07.05.2012Communication of intention to grant the patent
23.07.2012Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
08.11.2012Communication of intention to grant the patent
08.03.2013Fee for grant paid
08.03.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  27.04.2011
Opposition(s)20.01.2014No opposition filed within time limit [2014/13]
Fees paidRenewal fee
12.12.2007Renewal fee patent year 03
15.12.2008Renewal fee patent year 04
18.12.2009Renewal fee patent year 05
24.12.2010Renewal fee patent year 06
23.12.2011Renewal fee patent year 07
28.12.2012Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.12.2005
CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
LT17.04.2013
LV17.04.2013
MC17.04.2013
NL17.04.2013
PL17.04.2013
RO17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
TR17.04.2013
BG17.07.2013
GR18.07.2013
IS17.08.2013
PT19.08.2013
IE21.12.2013
LU21.12.2013
[2015/34]
Former [2015/32]CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
LT17.04.2013
LV17.04.2013
MC17.04.2013
NL17.04.2013
PL17.04.2013
RO17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
TR17.04.2013
BG17.07.2013
GR18.07.2013
IS17.08.2013
PT19.08.2013
IE21.12.2013
LU21.12.2013
Former [2014/48]CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
LT17.04.2013
LV17.04.2013
MC17.04.2013
NL17.04.2013
PL17.04.2013
RO17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
BG17.07.2013
GR18.07.2013
IS17.08.2013
PT19.08.2013
IE21.12.2013
LU21.12.2013
Former [2014/38]CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
LT17.04.2013
LV17.04.2013
MC17.04.2013
NL17.04.2013
PL17.04.2013
RO17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
BG17.07.2013
GR18.07.2013
IS17.08.2013
PT19.08.2013
LU21.12.2013
Former [2014/14]CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
LT17.04.2013
LV17.04.2013
NL17.04.2013
PL17.04.2013
RO17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
BG17.07.2013
GR18.07.2013
IS17.08.2013
PT19.08.2013
Former [2014/11]CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
LT17.04.2013
LV17.04.2013
PL17.04.2013
RO17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
BG17.07.2013
GR18.07.2013
IS17.08.2013
PT19.08.2013
Former [2014/10]CY17.04.2013
CZ17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
LT17.04.2013
LV17.04.2013
PL17.04.2013
SE17.04.2013
SI17.04.2013
SK17.04.2013
BG17.07.2013
GR18.07.2013
IS17.08.2013
PT19.08.2013
Former [2014/09]CY17.04.2013
DK17.04.2013
EE17.04.2013
FI17.04.2013
LT17.04.2013
LV17.04.2013
PL17.04.2013
SE17.04.2013
SI17.04.2013
BG17.07.2013
GR18.07.2013
IS17.08.2013
PT19.08.2013
Former [2013/52]CY17.04.2013
FI17.04.2013
LT17.04.2013
LV17.04.2013
PL17.04.2013
SE17.04.2013
SI17.04.2013
BG17.07.2013
GR18.07.2013
IS17.08.2013
PT19.08.2013
Former [2013/50]FI17.04.2013
LT17.04.2013
LV17.04.2013
PL17.04.2013
SE17.04.2013
SI17.04.2013
BG17.07.2013
GR18.07.2013
IS17.08.2013
PT19.08.2013
Former [2013/49]FI17.04.2013
LT17.04.2013
SE17.04.2013
SI17.04.2013
GR18.07.2013
IS17.08.2013
PT19.08.2013
Former [2013/48]LT17.04.2013
IS17.08.2013
PT19.08.2013
Former [2013/47]LT17.04.2013
PT19.08.2013
Documents cited:Search[A]WO9855623  (PANGENETICS BV [NL], et al) [A] 1-62* p. 8, claims, examples *;
 [X]WO0104145  (UNIV LAUSANNE [CH], et al) [X] 1-62 * p. 2, l. 12-p. 3, l. 21; p. 7, l. 7-8; seq ID:1 and 2; Table 2, p. 13; p. 18, l. 30-p. 23, l. 3; p. 23, l. 5-p. 29, l. 18; p. 34, l. 1-p. p. 37, l. 28; p. 45, l. 13-p. 48, l. 25; p. 70-71; examples 4 and 5 *
International search[X]JPH06141884  (HAGIWARA YOSHIHIDE);
 [X]US2004228592  (GAETA ALEXANDER L [US], et al);
 [X]  - AOTSUKA Y. ET AL., "Identification of a malignant cell associated antigen recognized by a human monoclonal antibody", EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, (198805), vol. 24, no. 5, pages 829 - 838, XP002974984

DOI:   http://dx.doi.org/10.1016/0277-5379(88)90191-5
 [X]  - HAGIWARA H. ET AL., "Determination of the antigen/epitope that is recognized by human monoclonal antibody CLN-IgG", HUMAN ANTIBODIES, (2001), vol. 10, no. 2, pages 77 - 82, XP002974980
 [Y]  - OSUMI K. ET AL., "Antibody dependent cell mediated cytotoxicity on human cervical carcinoma cell line, ME-180, with human monoclonal antibody", CANCER LETTERS, (1992), vol. 62, no. 2, pages 179 - 183, XP002974982

DOI:   http://dx.doi.org/10.1016/0304-3835(92)90190-7
 [Y]  - FENSTERMAKER R. ET AL., "Immunotherapeutic strategies for malignant glioma", CANCER CONTROL, (200405), vol. 11, no. 3, pages 181 - 191, XP008119219
 [X]  - SHIKHMAN A.R. ET AL., "Distinct pathways regulate facilitated glucose transport in human articular chondrocytes during anabolic and catabolic responses", AMERICAN JOURNAL OF PHYSIOLOGY - ENDOCRINOLOGY AND METABOLISM, (20040128), vol. 286, pages E980 - E985, XP008119220

DOI:   http://dx.doi.org/10.1152/ajpendo.00243.2003
 [Y]  - KREITMAN R.J., "Immunotoxins in cancer therapy", CURRENT OPINION IN IMMUNOLOGY, (1999), vol. 11, no. 5, pages 570 - 578, XP001012909

DOI:   http://dx.doi.org/10.1016/S0952-7915(99)00005-9
 [A]  - MOADEL R.M. ET AL., "Positherapy: targeted nuclear therapy of breast cancer with 18F-2-deoxy-2-fluoro-d-glucose", CANCER RESEARCH, (20050201), vol. 65, no. 3, pages 698 - 702, XP008119221
Examination   - Shin, B. et al (2004) J. Neurosci.Res. 75:835-844
    - Lisinski, I. et al (2001) Biochem. J. 358:517-522
by applicantWO9855623
 WO0104145
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.